<DOC>
	<DOC>NCT02523391</DOC>
	<brief_summary>The purpose of this study is to compare the pharmacokinetics of capsule and tablet formulations of TA-8995 in healthy male subjects aged 18 to 55 years.</brief_summary>
	<brief_title>Bioequivalence Study of Capsule and Tablet Formulations of TA-8995</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy males aged 1855 Body Mass Index (BMI) between 18.0 and 32.0 kg/m2, inclusive Subject has a known hypersensitivity to any of the inactive ingredients of the study treatments. Subject has any other condition which, in the Investigator's opinion will interfere with the study. Subjects who are still participating in another clinical study (eg, attending followup visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) within 3 months or 5 halflives (whichever is longer) prior to the first dose in this study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>